NCT06750471View on ClinicalTrials.gov

Dupixent Study for Alternate Administration

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Nasal PolypsSinusitisChronic Disease
Interventions
BIOLOGICAL

Dupilumab

Dupilumab is an anti-IL 4-13 biologic therapy that has been recently approved for use in recurrent chronic rhinosinusitis with nasal polyposis.

Trial Locations (1)

98431

Madigan Army Medical Center, Tacoma

All Listed Sponsors
collaborator

Tripler Army Medical Center

FED

collaborator

Fort Belvoir Community Hospital

FED

collaborator

William Beaumont Army Medical Center

FED

lead

Madigan Army Medical Center

FED